Cancer cells induce an in-situ immune-suppressive microenvironment, which is critical for tumor escape, growth, and metastasis. Recent studies have reported immune suppression from remote tumors, suggesting a systemic immune tolerance upon tumor burden. But the underlying mechanism(s) were largely unknown. In this study, we found that remote tumor bearing mice performed dramatically attenuated pathogenesis of Concanavalin A (Con A) induced acute hepatitis, as indicated by decreased release of alanine aminotransferase (ALT), alleviated tissue necrosis and reduced production of pro-inflammatory cytokines. Intracellular cytokine staining results showed that interferon-γ (IFN-γ) production in NKT cells, not CD4+ T cells, was significantly decreased upon tumor burden, suggesting an important role of NKT cells. We also found remarkably increased myeloid-derived suppressor cells (MDSCs) in tumor bearing mice, and depletion/transfer experiments demonstrated that these cells were responsible for the ameliorated hepatitis through inhibiting IFN-γ production of NKT cells. Further researches revealed that the inhibitory effects of MDSCs were mediated via membrane-bounded transforming growth factor β (TGF-β) in a cell contact dependent manner. Moreover, we presented evidence that the recruitment of MDSCs into liver in tumor bearing mice was mediated by CXC chemokine receptor 2 (CXCR2), and tumor-derived TGF-β was critical in up-regulating CXCR2 ligands (CXCL1/2/5) in liver tissue. In summary, our results defined a novel mechanism of liver immune suppression triggered by growing remote tumor, and provided possible therapeutic targets against these MDSCs.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: